Administration of voriconazole in disseminated penicilliosis marneffei: a retrospective study

Abstract

Abstract:

Objective The aim of this retrospective study is to evaluate the efficacy and safety of voriconazole in the treatment of Penicilliosis marneffei (PSM)patients with or without HIV infection in clinical setting.Methods The disseminated PSM patients who received intravenous voriconazole (6 mg/kg every 12 hours for the first 24 hours and then 4 mg/kg every 12 hours afterwards) as primary antifungal treatment were enrolled.The following duration of antifungal treatment varied at the discretion of investigators according to the response of the patients.Primary response was evaluated at Week 16 or at the end of treatment (EOT).Follow-up evaluations were performed at 6 months and 1 year after EOT.Results A total of seventeen patients enrolled in this study, three patients were not evaluable because the treatment discontinued prematurely.Among the remaining fourteen patients, thirteen had satisfied response to treatment, ten patients had complete response and three patients had partial response at Week 16.Only one patient was evaluated as failure.Follow-up assessments in eleven patients showed eight patients were cured and the remaining three patients relapsed at 6 months after EOT.Eight patients were assessed 1 year later, none of them relapsed.No adverse events associated to voriconazole were recorded during the treatment.Conclusion The results from our study suggest that voriconazole is an effective, well-tolerated therapeutic option for disseminated P.marneffei infection.

Key words: voriconazole, disseminated penicilliosis marneffei, efficacy, safety

CLC Number:

R519.8

WEI Jin-ying, OUYANG Yan-yin, CAI Shuang-qi, LIANG Hao, CAO Cun-wei. Administration of voriconazole in disseminated penicilliosis marneffei: a retrospective study[J]. Chinese Journal of Mycology, 2017, 12(2): 92-97.

References

[1] Ustianowski AP,Sieu TP,Day JN.Penicillium marneffei infection in HIV[J].Curr Opin Infect Dis,2008,21(1):31-36.
[2] 赵国庆,冉玉平,向耘.中国大陆马尔尼菲青霉病的临床表现及流行病学特征的系统评价[J].中国真菌学杂志,2007,2(2):68-72.
[3] Deng Z,Ribas JL,Gibson DW,et al.Infections caused by Penicillium marneffei in China and Southeast Asia:review of eighteen published cases and report of four more Chinese cases[J].Rev Infect Dis,1988,10(3):640-652.
[4] Kawila R,Chaiwarith R,Supparatpinyo K.Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand:a retrospective study[J].BMC Infect Dis,2013,13(1):464-468.
[5] Duong TA.Infection due to Penicillium marneffei,an emerging pathogen:review of 155 reported cases[J].Clin Infect Dis,1996,23(1):125-130.
[6] Vanittanakom N,Sirisanthana T.Penicillium marneffei infection in patients infected with human immunodeficiency virus[J].Curr Top Med Mycol,1997,8(1-2):35-42.
[7] Xi L,Lu C,Zhou X,et al.Fifteen cases of penicilliosis in Guangdong,China[J].Mycopathologia,2004,158(2):151-155.
[8] Sirisanthana T,Nelson KE.Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in Human Immunodeficiency Virus-infected patients[J].Clin Infect Dis,1998,26(5):1107-1110.
[9] Walsh TJ,Pappas P,Winston DJ,et al.Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J].N Engl J Med,2002,346(4):225-234.
[10] Zmeili OS,Soubani AO.Pulmonary aspergillosis:a clinical update[J].QJM,2007,100(6):317-334.
[11] Greer ND.Voriconazole:the newest triazole antifungal agent[J].Proc,2003,16(2):241-248.
[12] Guideline for prevention and treatment of opportunistic infections in HIV-infected adults and adolescent[EB/OL].(2005-12-12)http://aidsinfo.nih.gov/guidelines on 12/12/2015.
[13] Liu D,Liang L,Chen J.In vitro antifungal drug susceptibilities of Penicillium marneffei,from China[J].J Infect Chemother,2013,19(4):776-778.
[14] Mo D,Li X,Wei L,et al.In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei[J].Mycopathologia,2014,178(3):217-220.
[15] Doby EH,Jr BD,Blaschke AJ,et al.Therapeutic monitoring of voriconazole in children less than 3 years of age:a case report and summary of voriconazole concentrations for 10 children[J].Pediatr Infect Dis J,2012,31(6):632-635.
[16] Döring M,Eikemeier M,Cabanillas Stanchi KM,et al.Antifungal prophylaxis with posaconazole vs.fluconazole or itraconazole in pediatric patients with neutropenia[J].Eur J Clin Microbiol Infect Dis,2015,34(6):1189-1200.
[17] Espinel-Ingroff A,Boyle K,Sheehan DJ.In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods:review of the literature[J].Mycopathologia,2001,150(3):101-115.
[18] 李梦,廖万清.侵袭性真菌感染治疗新进展[J].中国真菌学杂志,2012,7(1):47-51.
[19] Perfect JR,Marr KA,Walsh TJ,et al.Voriconazole treatment for less-common,emerging,or refractory fungal infections[J].CID,2003,36(9):1122-1131.
[20] Supparatpinyo K,Schlamm HT.Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients[J].Am J Trop Med Hyg,2007,77(2):350-353.
[21] Supparatpinyo K,Nelson KE,Merz WG,et al.Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens[J].Antimicrob Agents Chemother,1993,37(11):2407-2411.